Granite Bio Raises $100M in Funding to Advance Immunology Research
Granite Bio, a clinical-stage immunology company based in Basel, Switzerland, has secured $100 million in funding to support its ongoing operations and research efforts.
The funding round included a $30 million Series A led by Versant Ventures and Novartis Venture Fund, as well as a $70 million Series B led by Forbion and Sanofi Ventures.
The company is focused on developing antibodies that target the underlying causes of various inflammatory, autoimmune, and fibrotic conditions. Its pipeline includes two novel antibodies designed to address significant market opportunities:
- GRT-001, which targets pro-inflammatory monocytes, crucial drivers of autoimmunity and inflammation. Preclinical studies in non-human primates have shown that GRT-001 effectively depletes pro-inflammatory monocytes while maintaining tissue-resident macrophages. The antibody is currently undergoing Phase 1a testing in healthy volunteers and is set to enter a Phase 1b trial in patients with inflammatory bowel disease.
- GRT-002, which blocks interleukin-3, a key player in autoimmune and type II inflammation, offering a new approach to treating itch and allergy. This molecule is in preclinical development and is expected to advance to clinical trials in 2026.
The leadership team at Granite Bio includes:
- Patrick Loustau, President, and CEO.
- Dominik Hartl, M.D., Chief Medical Officer.
- Gijs van den Brink, M.D., Ph.D., Chief Scientific Officer.
- Eliot Forster, Chairperson of the Board.
Stay tuned for more updates from Granite Bio as they continue to make advancements in the field of immunology.
Published by FinSMEs on 24/04/2025
